November 16, 2026

Struggles and Progress in Insulin Price Debate

The Kritzberger family, with a farming legacy in the Red River Valley spanning over a century, switched from livestock to cultivating crops like sugar beets, soybeans, and grains. They face significant financial challenges. “We’re in a lot of debt,” Ang Kritzberger admits while walking their farm.

For the last decade, their focus included health concerns. Their daughter, Nina, was diagnosed with Type 1 diabetes at age seven, introducing them to the broader national discussion on high insulin costs. Ang Kritzberger vividly recalls, “I stayed by her bed for 60 days, checking her blood every two hours to ensure her safety.” Despite insurance, the family’s medical expenses exceed $8,000 annually due to medicine, supplies, and appointments.

This high cost isn’t unusual. Skyrocketing insulin prices have led many diabetes patients to spend hundreds or even thousands of dollars, with some rationing the drug, often facing dire consequences. A national movement is now in place to cap out-of-pocket insulin expenses, bringing Democrats and Republicans together to address spiraling drug prices.

North Dakota state Sen. Sean Cleary, a Republican, emphasizes, “The market was broken, and consensus was required.” Last year, he helped pass legislation that caps insulin costs at $25 per month, making North Dakota one of 29 states enacting similar measures. This cap ensures patients only pay a fixed amount monthly, regardless of high deductibles for other medical needs.

The rising prices of insulin prompted the American Diabetes Association and other advocates to push for these caps. Nearly 20% of the 40 million Americans with diabetes require insulin for survival. The drug’s cost spikes mean the average out-of-pocket expense hit $470 annually in 2018. Pressure on pharmaceutical companies has since reduced this number to $220 by 2025.

For families like the Kritzbergers, government-imposed caps provide protection against future price hikes and some relief from the challenges of managing diabetes. Now 17, Nina Kritzberger faces daily hurdles, ensuring she has all necessary supplies and worrying about malfunctioning equipment. A missed dose can lead to hospitalization. “My body would break down,” she says grimly.

Initially, insulin copay caps gained traction among Democrats. Colorado pioneered such a cap in 2019, limiting the cost to $100 for a month’s supply. In 2022, a federal cap of $35 was introduced for Medicare recipients, though extending it to private insurance holders faced setbacks due to Republican opposition.

In North Dakota, Democrat state Sen. Tim Mathern pushed hard for a statewide copay cap. Despite resistance, citing potential insurance premium impacts, bipartisan support eventually helped pass the bill. Some lawmakers recognized persistent frustration with drug manufacturers and healthcare insurers, asking why a century-old drug costs so much.

State Rep. Carrie McLeod, also a Republican and diabetes educator, criticized the healthcare industry’s profit motives overtaking patient needs. “Insurance was meant for catastrophic needs,” she highlighted, “it’s out of control now.” The overwhelming bipartisan support for the insulin bill underscores growing unity in addressing healthcare costs.

While individual state regulations cover only some health plans, federal interest in a nationwide insulin price cap is growing. Notably, Sen. Kevin Cramer from North Dakota is among the bill’s co-sponsors. Public opinion backs price regulation, with around 70% of Americans believing more intervention is necessary.

Reflecting on these efforts from her farm, Ang Kritzberger sees a distilled lesson: North Dakotans value community connections and common ground. Neighbors once helped a farmer with cancer harvest crops. “That’s what it’s all about,” she says.

KFF Health News, a national newsroom focused on health journalism, originally published this article. It’s shared under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

TAGS: